Dulaglutide vs Tesamorelin

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Dulaglutide

Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.

Full details →

Tesamorelin

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.

Full details →

Side-by-Side Comparison

Aspect	Dulaglutide	Tesamorelin
Dose Range	750 mcg–4.5 mg	2 mg
Frequency	Less than daily	1x daily
Cycle Length	12–52 weeks	8–52 weeks
Route	subcutaneous	subcutaneous
Mechanism	GLP-1 analog fused to a modified human IgG4 Fc fragment, providing extended duration of action. Activates GLP-1 receptors for glucose-dependent insulin secretion and appetite suppression.	Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue.
Typical Dosage	Start at 0.75mg once weekly, may increase to 1.5mg, 3mg, or maximum 4.5mg weekly based on glycemic response.	FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules.
Administration	Subcutaneous injection once weekly, any time of day, with or without food. Comes in pre-filled single-dose pens.	Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening.
Side Effects	Nausea, diarrhea, vomiting, abdominal pain, decreased appetite. Generally well-tolerated with gradual dose titration.	Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose.
Best For	Fat Loss	Muscle Growth Fat Loss